Observational study on kidney transplant recurrence in FSGS and MCD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather data on patients with focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) who have undergone or will undergo kidney transplantation. It will collect both retrospective and prospective data, along with biospecimens and patient-reported information, to better understand the incidence and prevalence of disease recurrence post-transplant. The study seeks to create a biorepository to support future research into the mechanisms and outcomes of these kidney diseases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Retrospective non-consented participant group had a transplant from the year 2000 and onward.
* Diagnosis of FSGS or MCD in the native kidney (prior to transplant).

Exclusion Criteria:

* Pathologic diagnosis other than FSGS or MCD
* FSGS or MCD secondary to a known disorder (e.g. lupus nephritis, Immunoglobulin A (IgA) nephropathy, malignancy)

Where it's running

• University of Michigan
  Ann Arbor, Michigan, United States Recruiting

Study contacts

• Principal investigator: Eloise Salmon, MD — University of Michigan
• Study coordinator: Ashley Rahimi
• Email: asboggs@med.umich.edu
• Phone: 734-647-5446

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NEPTUNE Match: Personalized matching of patients to kidney treatment options

  This project will try a system that matches people in the NEPTUNE cohort who have nephrotic syndromes or related kidney diseases with suitable clinical trials and shares those matches with patients and their doctors.

  Recruiting at 15 sites University of Michigan · Atlanta, Georgia and 15 other locations · NCT04571658

• Safety, tolerability, and how the body handles SK-09

  This trial will test single and repeated oral doses of SK-09 for safety and to see how the body processes them in healthy adults aged 18–55.

  Recruiting Phase 1 Consun Pharmaceutical Group · Herston, Queensland · NCT07267026

• Atacicept for multiple autoimmune glomerular diseases

  This will test whether weekly injections of atacicept can lower protein in the urine and help preserve kidney function in people aged 10 and older with IgA nephropathy, primary membranous nephropathy, or nephrotic syndromes such as MCD and FSGS.

  Recruiting Phase 2 Vera Therapeutics, Inc. · Brisbane, California · NCT06983028

• Testing ManNAc for treating kidney disease FSGS

  This study is testing if a new oral treatment called ManNAc can help adults with kidney disease FSGS by reducing protein levels in their urine and checking how safe it is over 12 weeks.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06664814

• Vagus nerve stimulation for treating nephrotic syndrome in children

  This study is testing whether a new treatment using vagus nerve stimulation can help children aged 3 to 17 with nephrotic syndrome feel better and reduce their symptoms.

  Recruiting at 2 sites Northwell Health · New Hyde Park, New York and 1 other locations · NCT05588063

• Using vagus nerve stimulation to treat nephrotic syndrome in children

  This study is testing if a new type of nerve stimulation can help children with steroid-resistant nephrotic syndrome feel better over 26 weeks.

  Recruiting at 2 sites Northwell Health · New Hyde Park, New York and 1 other locations · NCT05583942

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.